{"classes":[{"categories":[{"measurements":[{"comment":"Later cycles are NA because 1 participant died after study entry with 1 cycle, and the other participant died after two cycles.","groupId":"OG000","spread":"NA","value":"24.1"},{"groupId":"OG001","spread":"31.4","value":"59.3"},{"groupId":"OG002","spread":"50.4","value":"56.5"},{"groupId":"OG003","spread":"52.7","value":"79.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"16"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"234.4","value":"58.9"},{"groupId":"OG002","spread":"47.4","value":"85.0"},{"groupId":"OG003","spread":"48.9","value":"148"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"8"}],"units":"Participants"}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"36.4","value":"99.2"},{"groupId":"OG002","spread":"41.1","value":"113"},{"groupId":"OG003","spread":"80.4","value":"121"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"title":"Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"19.8","value":"166"},{"groupId":"OG002","spread":"21.9","value":"145"},{"groupId":"OG003","spread":"8.10","value":"209"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"}],"units":"Participants"}],"title":"Cycle 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"16"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants \\<2 Age (Years)","id":"OG000","title":"<2 Age (Years)"},{"description":"Participants 2 to \\<12 Age (Years)","id":"OG001","title":"2 to <12 Age (Years)"},{"description":"Participants 12 to \\<18 Age (Years)","id":"OG002","title":"12 to <18 Age (Years)"},{"description":"Participants \\>=18 Age (Years)","id":"OG003","title":">=18 Age (Years)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Included PK population, defined as patients who had received any amount of study drug and had at least one serum concentration result available at clinical data cutoff. In the \"\\<2 Age (Years)\" Arm/Group, 1 participant died after study entry with 1 cycle, and the other participant died after two cycles.","reportingStatus":"POSTED","timeFrame":"PRD (0 hr) on D1 of Cy2,3,4,8, 12, 16 (1 Cy=21 days) and every 8 cycles thereafter; at any time during visit at study drug discontinuation visit, at least 90 days (maximum 150 days) after the last dose of study drug (up to approximately 42 months)","title":"Minimum Serum Concentration (Cmin) of Atezolizumab","type":"PRIMARY","unitOfMeasure":"ug/mL"}